Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WX-mPD-L1
- Development stage
- Preclinical
- Lead developer
- WuXi AppTec
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
WX-mPD-L1 is an anti-mouse programmed death-ligand 1 (PD-L1) monoclonal antibody developed by WuXi AppTec and WuXi Biologics. It is designed as a surrogate research tool for use in syngeneic mouse xenograft models to evaluate the efficacy and mechanism of action of immune checkpoint inhibitors in preclinical settings. The antibody blocks the interaction between PD-L1 and its receptor PD-1, thereby enhancing T-cell mediated anti-tumor immune responses. It has been utilized in studies involving melanoma cell lines like CloudmanS91 and B16-F10 to profile neo-antigens and TCR repertoires.
- Other names
- WuXi anti-mouse PD-L1
02
Targets
Beyond the preview
Go deeper on WX-mPD-L1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WX-mPD-L1.